RT Journal Article
SR Electronic
T1 Levodopa pharmacokinetics. Alterations after benserazide, a decarboxylase inhibitor.
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 164
OP 168
VO 6
IS 2
A1 Doller, H J
A1 Connor, J D
A1 Lock, D R
A1 Sloviter, R S
A1 Dvorchik, B H
A1 Vesell, E S
YR 1978
UL http://dmd.aspetjournals.org/content/6/2/164.abstract
AB Plasma levodopa decay curves appeared to be triexponential up to 6 hr after single intravenous injections of levodopa in rats, rabbits, and dogs. After pretreatment of each of these three species with benserazide (Ro-4-4602), a decarboxylase inhibitor, plasma levodopa concentrations declined biexponentially. Administration of benserazide decreased both total plasma clearance and apparent volume of distribution of levodopa, but did not change the rate constant of the terminal phase of the plasma levodopa decay curve. Thus, decarboxylase inhibition failed to alter the plasma half-life of levodopa.